首页> 美国卫生研究院文献>Frontiers in Oncology >Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort of Korean Patients

【2h】

Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort of Korean Patients

机译：2年和3年无病生存率是一项重要的早期替代指标可以预测膀胱膀胱癌根治性膀胱切除术治疗患者的5年总体生存期：一组韩国患者的外部评估和验证

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeWe aimed to externally validate the association of 2- and 3-year disease-free survival (DFS) with 5-year overall survival (OS) in patients treated with radical cystectomy (RC) for urothelial carcinoma (UC) of the bladder.

机译：目的我们的目标是从外部验证膀胱尿路上皮癌（UC）接受根治性膀胱切除术（RC）的患者的2年和3年无病生存期（DFS）与5年总生存期（OS）的关联。

著录项

期刊名称 Frontiers in Oncology
作者
Hyung Suk Kim; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku;
展开▼
作者单位

展开▼
年(卷),期 2015(5),-1
年度 2015
页码 246
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
urothelial carcinoma radical cystectomy surrogate disease-specific survival overall survival;

机译：尿路上皮癌;根治性膀胱切除术;替代;疾病特异性生存;总体生存;

相似文献

外文文献
专利

1. Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort of Korean Patients [J] . Hyung Suk Kim, Chang Wook Jeong, Cheol Kwak, Frontiers in Oncology . 2015,第6期

机译：2年和3年无病生存是一项重要的早期替代指标，可预测膀胱膀胱癌根治性膀胱切除术治疗患者的5年总体生存：一组韩国患者的外部评估和验证
2. External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder [J] . NuhnP., MayM., FritscheH.-M., European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology . 2012,第7期

机译：外部验证2或3年无病生存率是膀胱尿路上皮癌根治性膀胱切除术患者的替代和新的主要终点
3. The Cancer of the Bladder Risk Assessment (COBRA) score for predicting cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder: External validation in a cohort of Korean patients [J] . Kim Hyung Suk, Kwak Cheol, Kim Hyeon Hoe, Urologic oncology . 2019,第7期

机译：膀胱风险评估（COBRA）评分用于预测膀胱内切除术后癌症膀胱切除术后的癌症特异性生存率的癌症：韩国患者队列的外部验证
4. Predicting Disease-Free Lung Cancer Survival Using Patient Reported Outcome (PRO) Measurements with Comparisons of Five Machine Learning Techniques (MLT) [C] . Jin-ah Sim, Young Ho Yun MEDINFO . 2019

机译：使用患者报告的结果（PRO）测量来预测无病的肺癌存活，并使用五种机器学习技术（MLT）进行比较
5. Predicting Survival Among Colorectal Cancer Patients: Development and Validation of Polygenic Survival Score [D] . Maawadh, Rawan Mohammed. 2020

机译：预测结肠直肠癌患者的生存：多基因生存率的发展和验证
6. Multifactorial Site-Specific Recurrence Models after Radical Cystectomy for Urothelial Carcinoma: External Validation in a Cohort of Korean Patients [O] . Hyung Suk Kim, Myong Kim, Chang Wook Jeong, -1

机译：膀胱癌根治性膀胱切除术后多因素针对特定部位的复发模型：一组韩国患者的外部验证
7. Disease-free survival at 2 and 3 years is a significant early surrogate marker predicting the 5-year overall survival in patients treated with radical cystectomy for urothelial carcinoma of the bladder: external evaluation and validation in a cohort of Korean patients [O] . Hyung Suk eKim, Chang Wook eJeong, Cheol eKwak, 2015

机译：2年和3年的无病生存率是一个重要的早期替代指标，用于预测膀胱尿路上皮癌根治性膀胱切除术患者的5年总生存率：一组韩国患者的外部评估和验证

Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort of Korean Patients

摘要

著录项

相似文献

相关主题

期刊订阅